Impact of the Characteristics of Acute Renal Failure in Intensive Care on the Long-term Renal Prognosis: Prospective Multicenter Cohort Study
Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · Feb 9, 2022
Trial Information
Current as of July 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different characteristics of Acute Kidney Injury (AKI) affect the long-term health of the kidneys in patients who are in the Intensive Care Unit (ICU). The goal is to understand which factors might influence recovery and kidney function after a patient leaves the ICU. This research is important because it can help doctors provide better care and make more informed decisions for patients who experience kidney issues while critically ill.
To participate in this study, patients need to be at least 18 years old and have been hospitalized in the ICU for more than 24 hours. Unfortunately, patients who are pregnant, those needing a kidney transplant, or those with certain legal restrictions are not eligible. If selected to participate, patients can expect to be part of a multi-center study that closely monitors their kidney function over time. This trial is currently recruiting participants, and it aims to gather valuable information that could improve kidney care for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who are hospitalized for more than 24 hours in ICU will be eligible to participate in the study.
- Exclusion Criteria:
- • patients who are younger than 18 years,
- • those who are pregnant,
- • those who have chronic extrarenal epuration before their admission to the ICU,
- • those who are admitted for kidney transplantation,
- • those under the safeguard of justice, and those who refuse to participate in the study.
About University Hospital, Clermont Ferrand
The University Hospital of Clermont-Ferrand is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. Renowned for its multidisciplinary approach, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes collaboration among healthcare professionals, researchers, and academic partners. With a strong commitment to improving patient outcomes, the institution actively engages in a wide array of clinical studies, ranging from early-phase trials to large-scale interventions, aimed at addressing critical health challenges and enhancing treatment modalities. Its state-of-the-art facilities and expertise make it a pivotal contributor to clinical research in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Clermont Ferrand, , France
Clermont Ferrand, , France
Patients applied
Trial Officials
Alexandre Lautrette
Principal Investigator
University Hospital, Clermont-Ferrand
Cécile Gosset
Principal Investigator
University Hospital, Clermont-Ferrand
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials